LIMN Stock Analysis: Buy, Sell, or Hold?
LIMN - Liminatus Pharma, Inc. Class A Common Stock
$0.10
-0.01 (-10.66%)
▼
5d:
-28.33%
30d:
-25.67%
90d:
-45.49%
WAIT
LOW Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Jun 30, 2026
0d
Get Alerted When LIMN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
5 traders called LIMN this week
89% bullish • 1 bearish
89% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: LIMN is down 28.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: LIMN is down 28.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: LIMN is currently trading at $0.10, which is considered oversold relative to its 30-day fair value range of $0.11 to $0.14.
Technical Outlook: Technically, LIMN is in a downtrend. The price is currently testing key support at $0.13. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LIMN is in a downtrend. The price is currently testing key support at $0.13. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.11 -
$0.14
Company Quality Score
49/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
68.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BEARISH: Downward momentum (-10.7%)
- WARNING: Recommendation downgraded due to -28.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.11 -
$0.14
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.13
Resistance Level
$0.21
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Share & Embed Analysis
Last updated: July 13, 2026 12:43 PM ET
Data refreshes hourly during market hours. Next update: 1:43 PM
Data refreshes hourly during market hours. Next update: 1:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LIMN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 57 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 58 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$200 | 65 BUY |